These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

European stocks rose sharply Friday after U.S. Commerce Secretary Howard Lutnick said the U.S. and China had agreed to restore their trade truce and that more deals were imminent. Also lifting the ...

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...